Showing 4,221 - 4,240 results of 14,107 for search '(( significant decrease decrease ) OR ( significant ((i decrease) OR (a decrease)) ))~', query time: 0.56s Refine Results
  1. 4221

    Image 6_Deciphering the oncogenic network: how C1QTNF1-AS1 modulates osteosarcoma through miR-34a-5p and glycolytic pathways.tif by Yu Zhang (12946)

    Published 2025
    “…</p>Results<p>The findings indicated a significant decrease in C1QTNF1-AS1 expression levels in OS cells compared to normal osteoblasts. …”
  2. 4222

    Image 1_Deciphering the oncogenic network: how C1QTNF1-AS1 modulates osteosarcoma through miR-34a-5p and glycolytic pathways.tif by Yu Zhang (12946)

    Published 2025
    “…</p>Results<p>The findings indicated a significant decrease in C1QTNF1-AS1 expression levels in OS cells compared to normal osteoblasts. …”
  3. 4223

    Image 13_Deciphering the oncogenic network: how C1QTNF1-AS1 modulates osteosarcoma through miR-34a-5p and glycolytic pathways.tif by Yu Zhang (12946)

    Published 2025
    “…</p>Results<p>The findings indicated a significant decrease in C1QTNF1-AS1 expression levels in OS cells compared to normal osteoblasts. …”
  4. 4224

    Table 1_Deciphering the oncogenic network: how C1QTNF1-AS1 modulates osteosarcoma through miR-34a-5p and glycolytic pathways.docx by Yu Zhang (12946)

    Published 2025
    “…</p>Results<p>The findings indicated a significant decrease in C1QTNF1-AS1 expression levels in OS cells compared to normal osteoblasts. …”
  5. 4225

    Image 15_Deciphering the oncogenic network: how C1QTNF1-AS1 modulates osteosarcoma through miR-34a-5p and glycolytic pathways.tif by Yu Zhang (12946)

    Published 2025
    “…</p>Results<p>The findings indicated a significant decrease in C1QTNF1-AS1 expression levels in OS cells compared to normal osteoblasts. …”
  6. 4226

    Image 11_Deciphering the oncogenic network: how C1QTNF1-AS1 modulates osteosarcoma through miR-34a-5p and glycolytic pathways.tif by Yu Zhang (12946)

    Published 2025
    “…</p>Results<p>The findings indicated a significant decrease in C1QTNF1-AS1 expression levels in OS cells compared to normal osteoblasts. …”
  7. 4227

    Image 12_Deciphering the oncogenic network: how C1QTNF1-AS1 modulates osteosarcoma through miR-34a-5p and glycolytic pathways.tif by Yu Zhang (12946)

    Published 2025
    “…</p>Results<p>The findings indicated a significant decrease in C1QTNF1-AS1 expression levels in OS cells compared to normal osteoblasts. …”
  8. 4228

    Image 9_Deciphering the oncogenic network: how C1QTNF1-AS1 modulates osteosarcoma through miR-34a-5p and glycolytic pathways.tif by Yu Zhang (12946)

    Published 2025
    “…</p>Results<p>The findings indicated a significant decrease in C1QTNF1-AS1 expression levels in OS cells compared to normal osteoblasts. …”
  9. 4229

    Table 9_Deciphering the oncogenic network: how C1QTNF1-AS1 modulates osteosarcoma through miR-34a-5p and glycolytic pathways.xlsx by Yu Zhang (12946)

    Published 2025
    “…</p>Results<p>The findings indicated a significant decrease in C1QTNF1-AS1 expression levels in OS cells compared to normal osteoblasts. …”
  10. 4230

    ASP protects the AC16 cells from DOX-induced cardiotoxicity via Nrf2 activation. by Xueyang Bai (20550422)

    Published 2025
    “…<p>(A) Representative images of protein expression detected by Western blot of p-PI3K,p-AKT, AKT, and the Nrf2 downstream signaling pathways in AC16 cells; (B, C) ML385 does not affect PI3K/AKT (n = 3); (D-F) The statistical results show that ML385 significantly represses NRF2 activation, leading to a decrease in its downstream gene expression (n = 3); (G, H) Lipid ROS levels (n = 3); (I, J) Quantitative q-PCR analysis of relative ANP and BNP mRNA expression (n = 3); (K, L) Representative images (Scale bar =  100 μm) and statistical analysis of JC-1 (n = 150); One-way ANOVA (Tukey post-test), means ±  SD. …”
  11. 4231
  12. 4232

    Plant Extracellular Nanovesicle-Loaded Hydrogel for Topical Antibacterial Wound Healing <i>In Vivo</i> by Saroj Saroj (13749336)

    Published 2024
    “…The developed HG was injectable, biocompatible (>95% cell was viable), nonhemolytic (<5% hemolytic capacity), self-healing and exhibited strong physical and mechanical interactions with the bacteria cells (MENV-HG-treated bacteria were significantly more elastic compared to the control in both M. luteus (1.01 ± 0.3 MPa, <i>p</i> < 0.005 vs 5.03 ± 2.6) and E. coli (5.81 ± 2.1 MPa vs 10.81 ± 3.8, <i>p</i> < 0.005). …”
  13. 4233

    Plant Extracellular Nanovesicle-Loaded Hydrogel for Topical Antibacterial Wound Healing <i>In Vivo</i> by Saroj Saroj (13749336)

    Published 2024
    “…The developed HG was injectable, biocompatible (>95% cell was viable), nonhemolytic (<5% hemolytic capacity), self-healing and exhibited strong physical and mechanical interactions with the bacteria cells (MENV-HG-treated bacteria were significantly more elastic compared to the control in both M. luteus (1.01 ± 0.3 MPa, <i>p</i> < 0.005 vs 5.03 ± 2.6) and E. coli (5.81 ± 2.1 MPa vs 10.81 ± 3.8, <i>p</i> < 0.005). …”
  14. 4234

    Example of sample data. by Xiying Wang (4859998)

    Published 2025
    “…Under a standalone BPNN, the absolute relative error in flow prediction is 1.09%. …”
  15. 4235

    Structure of BPNN. by Xiying Wang (4859998)

    Published 2025
    “…Under a standalone BPNN, the absolute relative error in flow prediction is 1.09%. …”
  16. 4236

    The workflow of EGA-BPNN. by Xiying Wang (4859998)

    Published 2025
    “…Under a standalone BPNN, the absolute relative error in flow prediction is 1.09%. …”
  17. 4237

    Algorithm flow of the GA-BPNN model. by Xiying Wang (4859998)

    Published 2025
    “…Under a standalone BPNN, the absolute relative error in flow prediction is 1.09%. …”
  18. 4238
  19. 4239
  20. 4240

    Effects of liposomal bupivacaine (LB) and provider experience with LB on service utilization, clinical outcomes, and Medicare expenditures among fee-for-service (FFS) beneficiaries by Sarmistha Pal (13348959)

    Published 2025
    “…</p> <p>LB use contributed to significant reductions in ED admission (9%; 23.28 vs. 25.69%), STACH admission (8%; 11.61 vs. 12.65%), mortality (39%; 0.67 vs. 1.1%) and opioid prescription fills (6%; 1.8 vs. 1.92) within 180-days post-discharge. …”